Regeneron Pharmaceuticals buys Sanofi's rights to cemiplimab, a joint drug with the trade name Libtayo. Cemiplimab is a PD-1 inhibitor for cancer immunotherapy. Sanofi will receive $900 million and a royalty of 11% of net sales. In addition, the company will be entitled to $100 million after FDA or EC approval of the drug as first-line therapy for non-small cell lung cancer in combination with chemotherapy, and up to another $100 million depending on sales volume over the next 2 years. The deal is scheduled to close in Q3 2022.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept